Aurinia Pharmaceuticals Inc (AUP):企業財務及び戦略的SWOT分析

GlobalDataが発行した調査報告書(GDPH463030FSA)
◆英語タイトル:Aurinia Pharmaceuticals Inc (AUP) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH463030FSA
◆発行会社(リサーチ会社):GlobalData
◆発行日:2017年1月13日
◆ページ数:25
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:カナダ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD300 ⇒換算¥32,700見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD600 ⇒換算¥65,400見積依頼/購入/質問フォーム
Enterprisewide License(複数国内共有可)USD900 ⇒換算¥98,100見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Aurinia Pharmaceuticals Inc (Aurinia Pharmaceuticals) focuses on the development and commercialization of therapies for the treatment of autoimmune diseases. The company’s lead product candidate includes voclosporin, a novel therapeutic immunomodulating differentiated calcineurin inhibitor that is used for the treatment of lupus nephritis, an inflammation of the kidney caused by systemic lupus erythematosus. voclosporin is also used in indications such as prevention of rejection in renal transplantation. It works in partnership with Paladin Labs Inc. and 3SBio Inc. to develop and commercialize biopharmaceutical products globally. Aurinia Pharmaceuticals is headquartered in Victoria, British Columbia, Canada.

Aurinia Pharmaceuticals Inc Key Recent Developments

Dec 12, 2016: Aurinia Announces Appointment of Biotech Industry Leader Jeffry Randall to its Board of Directors and Audit Committee
Nov 04, 2016: Aurinia Reports Third Quarter 2016 Financial Results and Operational Highlights
Aug 05, 2016: Aurinia Reports Second Quarter 2016 Financial Results and Operational Highlights
Jul 11, 2016: Aurinia Announces Appointment of Head of Communications & Advocacy
Jun 28, 2016: Aurinia Announces 24 Week Remission Rates from the First Seven Patients in its Open Label AURION Study in Lupus Nephritis

This comprehensive SWOT profile of Aurinia Pharmaceuticals Inc provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

This company report forms part of GlobalData’s ‘Profile on Demand’ service, covering over 50,000 of the world’s leading companies. Once purchased, GlobalData’s highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of Aurinia Pharmaceuticals Inc including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. (excluding weekends).

The profile contains critical company information including*,

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note*: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include,

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

【レポートの目次】

Table of Contents

Section 1 – About the Company

Aurinia Pharmaceuticals Inc – Key Information
Aurinia Pharmaceuticals Inc – Overview
Aurinia Pharmaceuticals Inc – Key Employees
Aurinia Pharmaceuticals Inc – Key Employee Biographies
Aurinia Pharmaceuticals Inc – Key Operational Heads
Aurinia Pharmaceuticals Inc – Major Products and Services
Aurinia Pharmaceuticals Inc – History
Aurinia Pharmaceuticals Inc – Company Statement
Aurinia Pharmaceuticals Inc – Locations And Subsidiaries
Aurinia Pharmaceuticals Inc – Key Manufacturing facilities
Head Office
Other Locations & Subsidiaries

Section 2 – Company Analysis

Aurinia Pharmaceuticals Inc – Business Description
Aurinia Pharmaceuticals Inc – Corporate Strategy
Aurinia Pharmaceuticals Inc – SWOT Analysis
SWOT Analysis – Overview
Aurinia Pharmaceuticals Inc – Strengths
Aurinia Pharmaceuticals Inc – Weaknesses
Aurinia Pharmaceuticals Inc – Opportunities
Aurinia Pharmaceuticals Inc – Threats
Aurinia Pharmaceuticals Inc – Key Competitors

Section 3 – Company Financial Performance Charts

Aurinia Pharmaceuticals Inc – Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts

Section 4 – Appendix

Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

Note*: Some sections may be missing if data is unavailable for the company

List of Tables

Aurinia Pharmaceuticals Inc, Key Information
Aurinia Pharmaceuticals Inc, Key Ratios
Aurinia Pharmaceuticals Inc, Share Data
Aurinia Pharmaceuticals Inc, Major Products and Services
Aurinia Pharmaceuticals Inc, History
Aurinia Pharmaceuticals Inc, Key Employees
Aurinia Pharmaceuticals Inc, Key Employee Biographies
Aurinia Pharmaceuticals Inc, Key Operational Heads
Aurinia Pharmaceuticals Inc, Other Locations
Aurinia Pharmaceuticals Inc, Subsidiaries
Aurinia Pharmaceuticals Inc, Key Manufacturing facilities
Aurinia Pharmaceuticals Inc, Key Competitors
Aurinia Pharmaceuticals Inc, SWOT Analysis
Aurinia Pharmaceuticals Inc, Ratios based on current share price
Aurinia Pharmaceuticals Inc, Annual Ratios
Aurinia Pharmaceuticals Inc, Interim Ratios
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures

Aurinia Pharmaceuticals Inc, Performance Chart
Aurinia Pharmaceuticals Inc, Ratio Charts

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Aurinia Pharmaceuticals Inc (AUP):企業財務及び戦略的SWOT分析(Aurinia Pharmaceuticals Inc (AUP) - Financial and Strategic SWOT Analysis Review)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆